纳米载体
纳米技术
临床试验
材料科学
纳米材料
医学
药物输送
内科学
作者
Ruibo Zhao,Lawrence Jordan Keen,Xiangdong Kong
标识
DOI:10.1002/9783527698646.ch19
摘要
This chapter describes the successful clinical applications or continuing investigations in clinical trials of nanobiomaterials in different categories, highlighting nanobiomaterials that have either been recently approved or are already in clinical trials. It explains areas of safety regulation and policy of nanobiomaterials that are required in clinical translation. The chapter provides brief introduction of the key examples of nanobiomaterials in clinical or preclinical trials. In the future, nanobiomaterials may likely to raise questions of physical enhancement, social justice, and access to health care. Liposomal nanomaterials have shown an ability to improve the pharmacokinetics and pharmacodynamics of conjugated drugs. Nanocarriers are generally below 100nm in size and may be constructed from a wide range of organic, inorganic, and metallic nanoparticles such as polymers, calcium phosphate (CaP), gold, iron oxide, quantum dots (QDs), and carbon nanotubes (CNTs). Degradability of nanomaterial is an important factor of acute and long-term toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI